KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera Therapeutics (KYMR) shares declined 6.91% in after-market trading following a mixed operational update. Partner Sanofi opted to discontinue development of the Phase IIb drug KT-474, instead advancing the preclinical KT-485, which delays potential milestone payments for Kymera. This setback was partially offset by a new oncology collaboration with Gilead (GILD) for a CDK2 degrader program, providing an $85 million upfront payment and up to $750 million in potential milestones. Concurrently, Kymera launched a $250 million underwritten public offering of common stock, contributing to investor concerns over equity dilution.

Analysis

Kymera Therapeutics (KYMR) is undergoing a significant strategic re-alignment, characterized by a major clinical setback, a promising new partnership, and a dilutive capital raise. The discontinuation of the Phase IIb IRAK4 degrader, KT-474, by partner Sanofi represents a material negative development, effectively resetting the timeline for this program to a preclinical stage with the candidate KT-485. This pivot delays significant potential milestone payments and pushes out the commercial horizon for the IRAK4 franchise. Counterbalancing this news is a new exclusive license agreement with Gilead for a CDK2 degrader program, which provides an immediate $85 million upfront payment and validates Kymera's platform in the competitive oncology space. However, the positive impact of the Gilead deal was overshadowed by the concurrent announcement of a $250 million stock offering, which introduces immediate equity dilution. The market's reaction, a 6.91% after-hours stock decline, indicates that investors are weighing the near-term disappointment and dilution more heavily than the long-term potential of the new Gilead collaboration, despite the stock's strong 15.5% year-to-date outperformance against its industry.

Key Decisions for Investors

• Investors should re-evaluate their valuation models for Kymera, factoring in the delayed revenue timeline from the Sanofi partnership due to the shift from a Phase IIb asset to a preclinical one.
• The new Gilead collaboration provides a significant non-dilutive capital infusion and a new long-term catalyst in oncology; progress on this CDK2 program should be monitored closely as a key future value driver.
• Anticipate continued share price volatility and potential downward pressure in the short-term, driven by the dilutive impact of the $250 million stock offering and negative sentiment surrounding the KT-474 discontinuation.
• The capital raise, while dilutive, significantly strengthens Kymera's balance sheet, providing a longer cash runway to advance its independent clinical and preclinical programs.